Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Non-Current Assets data on file, last reported at $153.2 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets rose 25.75% year-over-year to $153.2 million; the trailing twelve-month figure through Dec 2025 stood at $577.8 million (up 36.49% YoY), and the FY2025 full-year result was $153.2 million, up 25.75% from the prior year.
• Non-Current Assets for Q4 2025 stood at $153.2 million, up from $147.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $153.2 million in Q4 2025 and bottomed at $51.5 million in Q3 2022.
• The 5-year median for Non-Current Assets is $95.3 million (2023), against an average of $91.3 million.
• The widest annual swing landed in 2021, when Non-Current Assets plunged 39.74%; it then soared 89.67% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $58.6 million in 2021, then advanced by 10.06% to $64.5 million in 2022, then jumped by 55.15% to $100.1 million in 2023, then advanced by 21.7% to $121.8 million in 2024, then grew by 25.75% to $153.2 million in 2025.
• The last three Non-Current Assets figures came in at $153.2 million (Q4 2025), $147.4 million (Q3 2025), and $146.7 million (Q2 2025), per Business Quant data.

Peer Comparison